# Proteon Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteon-pharmaceuticals-s-a

- Industry: Biotechnology
- Headquarters: Lodz, Poland
- Website: www.proteonpharma.com
- Total disclosed funding: $4.1M
- Latest round: Series A (Oct 24, 2017)
- Investors on record: 1

## About

Proteon Pharmaceuticals S.A. is a biotechnology company focused on developing bacteriophage-based solutions aimed at improving animal health and sustainability in livestock and aquaculture industries.Founded in 2005 by Jaroslaw Dastych in Lodz, Poland, Proteon Pharmaceuticals specializes in innovative health solutions for livestock and aquaculture. The company has engaged in two funding deals, with the latest in August 2021, raising EUR 21 million. Jaroslaw Dastych, who has a history of entrepreneurship, leads the firm as CEO.Proteon Pharmaceuticals specializes in bacteriophage-based solutions for livestock and aquaculture, designed to enhance animal health and sustainability in protein production. Their core products include phage cocktails that prevent and treat bacterial infections in various species, particularly poultry, fish, and dairy cattle. These solutions help modulate the microbiome to support gut health and immune function, thereby improving animal performance and reducing antibiotic reliance. Key offerings, such as BAFASAL®, effectively target pathogens like Salmonella in poultry, addressing the need for alternatives to traditional antibiotics while serving markets across Europe, South America, and parts of Asia.In the most recent year, 2023, Proteon Pharmaceuticals reported revenue of EUR 1,000,812.20 with an EBITDA of EUR -5,832,806.80. The company generates revenue through direct sales of its bacteriophage-based products to livestock and aquaculture firms, engaging in B2B partnerships that enhance animal health and productivity, thereby supporting steady market demand through tailored solutions.In August 2021, Proteon Pharmaceuticals S.A. raised EUR 21 million in venture funding, co-led by Aqua-Spark, with additional participation from Nutreco and the Polish Development Fund, among others. The company plans to use this funding to accelerate the commercialization of its products in aquaculture and livestock farming, while also developing its microbiome platform technology. Future initiatives include launching new products designed to enhance their market offerings and expanding into additional geographic markets, targeting regions that prioritize sustainable agricultural practices.

## Funding rounds

- Series A, Oct 24, 2017, $4.1M — Aqua-Spark

## Investors

- Aqua-Spark (https://capitalatlas.ai/funds/aqua-spark) — Series A